Measuring body composition in people with lung scarring who take anti-fibrotic medicines
Looks at body composition changes in adults with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- Royal Brompton HospitalLondon, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal Brompton & Harefield NHS Foundation Trust
- Trial code
- NCT07332117
- Record updated
- 12 January 2026
- Original description
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasoundRead full original descriptionShow less
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
Inclusion: A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis; Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone); Subject aged > 18 years; Able to willingly give consent.
Exclusion: Previous anti-fibrotic use; Currently on > Prednisolone 10mg daily; Heart failure; Co-morbidities currently requiring enteral feeding; Weight loss > 10% in preceding 3-6 months; Significant musculoskeletal issues that may impact muscle mass; End of life care (expected < 6 weeks left to live); Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM); Pregnancy.